![]() Abstracts can be accessed on the ESC Congress 2016 website. The complete list of Bristol-Myers Squibb and Pfizer Alliance presentations is included below. “This year at ESC Congress 2016, we’ll be discussing new NVAF and VTE data that complement our robust body of clinical trial data.” “As patient and provider needs continue to evolve, it’s essential that we deepen our understanding of how medicines are working in real-world situations,” said Jack Lawrence, M.D., Vice President, Cardiovascular Specialty Development, Bristol-Myers Squibb. 37 Part 1 of two phase 3 clinical trials ANNEXA-A and ANNEXA-R was recently completed. “We look forward to the opportunity to contribute to the scientific discussion and continued research during ESC Congress 2016.” The antidote was well tolerated and there were no serious or severe AEs and no thrombotic events. “The Bristol-Myers Squibb and Pfizer Alliance is pleased to share 19 abstracts, which include new real-world analyses, as well as new sub-analyses from the pivotal Phase 3 ARISTOTLE trial,” said Rory O’Connor, M.D., Chief Medical Officer, Internal Medicine, Pfizer Innovative Health. Degree of reversal can be assessed with PTT and/or plasma-diluted thrombin time (UWMedicine: DTI assay DTIPAT) betrixaban (Bevyxxa) 19-27 hours (longer in renal impairment) Unknown There is no assay for betrixaban at this time. Of note, several of the real-world data analyses are part of ACROPOLIS™ ( A pixaban Experien C e Through R eal-W O rld PO pu L at I on S tudies), a global real-world data research program designed to further evaluate the effectiveness and safety of apixaban in routine clinical practice. These new data from post-hoc analyses from ARISTOTLE ( A pixaban for R eduction I n ST roke and O ther T hromboembo L ic E vents in Atrial Fibrillation) and retrospective real-world data analyses continue to underscore the Alliance’s commitment to the evaluation of Eliquis for patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). (NYSE: PFE) announced today that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at ESC Congress 2016, to be held August 27–31 in Rome, Italy. Research and Business Development Partnershipsīristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.Unleashing the next wave of scientific innovations
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |